How to read an FDA recall notice

On Oct. 13, 2026, a manufacturer began recalling vials of argatroban injection, a hospital blood thinner, after particles of cellulose, plastic, stainless steel or stopper material were found in the solution. FDA classified the recall as Class I, its most serious category, on Oct. 26, and two days later it appeared in the agency's weekly Enforcement Report as two entries covering 18,991 vials and 1,944 vials, according to openFDA's record of the event³.

No press release was needed for pharmacists to act on it. The Enforcement Report entry carried everything that mattered: product, strength, package, lot numbers with expiration dates, distribution and status. FDA says the report includes all recalls it monitors¹, whether Class I, II, III or not yet classified, as described in 21 CFR 7.50⁹. Most of them never reach the news.

Patients see these notices more often than they used to, through pharmacy messages, news alerts and sites like this one. Every field in an entry has a fixed meaning, and reading them in the right order answers the only question most people have: is the medicine in my cabinet from an affected lot? The argatroban entry works as a specimen, and the same check applies to any medicine in a cabinet. GxRadar's shorter guide on how to check if your medicine was recalled covers the search tools.

Anatomy of one entry

Below, each field is paired with FDA's own definition, from its Enforcement Report definitions page², and with what the October 2026 argatroban entry showed. The firm's name is left out here, as it is everywhere on GxRadar.

Two details in that entry trip people up. First, the year. Drug recall numbers carry a suffix that generally follows the federal fiscal year, which starts Oct. 1, so a recall posted in October 2026 is numbered 2027. Second, the count. One event produced two recall numbers because it covered two separate product listings, and a recall of three strengths of a tablet would produce three. Quote the recall number when asking a pharmacist about a specific product.

Distribution needs care too. FDA's definitions² describe the pattern as the general area of initial distribution and note that later distribution by the firm's customers to other parties may not be included. A regional pattern does not rule anyone out.

Product description and code information decide it

Start with the product description. It names the medicine, strength, dosage form and package, and usually lists one or more National Drug Codes. An NDC identifies the labeler, the product and the package size; GxRadar's NDC explainer shows how to read one. If you have the manufacturer's bottle or carton, the NDC is printed on it, and DailyMed⁸, the National Library of Medicine's database of labels submitted to FDA, will match an NDC to its product and package.

Then the code information. It lists the affected lots, usually with expiration dates, and it is the field that decides whether a given unit is included. A recall that names specific lots covers only those lots. If your product's lot is absent, the recall does not cover it, even when the drug name and strength match exactly. Where the lot number sits on a package is covered in GxRadar's guide to lot numbers and expiration dates, and what a pharmacy vial label shows in how to read a prescription label.

Recall details can change after first publication, for instance when more lots are added. And openFDA notes³ that FDA does not update a recall's status in its data after the recall is classified, so the live Enforcement Report is the better place to check the current state.

The reason field and the class

Reasons are written as brief standard phrases such as CGMP Deviations, Failed Dissolution Specifications, Lack of Assurance of Sterility or Subpotent Drug, often followed by a sentence of detail. They describe the defect. For urgency, the class is the better guide. Under FDA's recall regulations in 21 CFR Part 7⁵, Class I covers situations with a reasonable probability of serious adverse health consequences or death, Class II covers temporary or medically reversible problems, and Class III covers products unlikely to cause adverse health consequences.

Class II dominates the record. GxRadar's tally of openFDA drug enforcement data³ from June 2012 through Oct. 28, 2026, is below, with the full breakdown by year and reason on the recalls page.

Fewer than one record in 10 was Class I; GxRadar looks at those in what FDA's Class I recall records show. Sterility and contamination problems were the largest reason group in GxRadar's grouping of the same records, at 9,273 records, a pattern GxRadar's piece on common reasons for drug recalls looks at in more depth.

Checking your own medicine

Match the drug name, strength and dosage form first. A recall of 10 mg tablets does not cover 20 mg tablets unless they are listed. Then find the manufacturer and NDC. If the medicine came in the manufacturer's original packaging, both are printed on it. If it was poured into a pharmacy vial, the label may name the manufacturer but not the original lot.

Next, compare lot numbers. FDA's consumer guidance on recalls⁶ tells patients to compare the lot number on their medicine with the lots listed in the notice. When the lot is not on your label, the pharmacy is the shortcut: pharmacies keep dispensing records and can often say which manufacturer and lot filled a prescription.

FDA's guidance is to ask before changing anything. The same FDA guidance⁶ says that for Class II and III recalls patients can generally keep taking the medicine unless the company or FDA says otherwise, and that stopping can sometimes be more harmful than continuing. For Class I recalls, FDA tells patients to follow the recalling company's instructions. In every case it directs questions to a doctor or pharmacist.

FDA followed that pattern during the 2018 recalls of certain angiotensin receptor blockers for nitrosamine impurities. Its ARB recall page⁷ told patients to check the manufacturer, NDC and lot number on their bottle against the agency's list, and to talk with a pharmacist or doctor about a replacement before stopping. GxRadar's history of the nitrosamine recalls follows what came next, and the valsartan and losartan pages show each drug's recall record.

Where the notices are published

The FDA Enforcement Report¹ is the complete weekly list, searchable by product, class and date. FDA's recall announcements page carries company press releases, which are useful but cover only a minority of recalls by design. openFDA³ offers the same enforcement records as a free API, from June 2012 onward, updated weekly, with a field reference⁴ that maps each API field to the report. FDA cautions that the openFDA data should not be used to make decisions about medical care. Pharmacies receive notices through their wholesalers and may contact patients when a recall reaches the consumer level. GxRadar's radar feed lists new entries as they post.

Read the status line last. Terminated means FDA has concluded that all reasonable efforts to remove or correct the product have been made; Completed means the firm reports it has recovered what it reasonably can; Ongoing means the work continues. Any of the three can apply to old stock still sitting in a cabinet, which is why the lot number stays the deciding detail. The argatroban entry was still listed as Ongoing when FDA last refreshed its data on Oct. 28, 2026; the next weekly report will show whether more lots were added.